RU2348409C2 - Способ снижения желудочно-кишечной токсичности, возникающей в результате применения тегафура - Google Patents

Способ снижения желудочно-кишечной токсичности, возникающей в результате применения тегафура Download PDF

Info

Publication number
RU2348409C2
RU2348409C2 RU2006142101/14A RU2006142101A RU2348409C2 RU 2348409 C2 RU2348409 C2 RU 2348409C2 RU 2006142101/14 A RU2006142101/14 A RU 2006142101/14A RU 2006142101 A RU2006142101 A RU 2006142101A RU 2348409 C2 RU2348409 C2 RU 2348409C2
Authority
RU
Russia
Prior art keywords
tegafur
patient
acid
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2006142101/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2006142101A (ru
Inventor
Наруо НОМУРА (умер)
Такеси ТАХАРА (JP)
Такеси ТАХАРА
Хироси АМБЕ (JP)
Хироси АМБЕ
Дзун КУРИТАНИ (SG)
Дзун КУРИТАНИ
Original Assignee
Тайхо Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайхо Фармасьютикал Ко., Лтд. filed Critical Тайхо Фармасьютикал Ко., Лтд.
Publication of RU2006142101A publication Critical patent/RU2006142101A/ru
Application granted granted Critical
Publication of RU2348409C2 publication Critical patent/RU2348409C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2006142101/14A 2004-04-29 2005-04-27 Способ снижения желудочно-кишечной токсичности, возникающей в результате применения тегафура RU2348409C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
US60/566,180 2004-04-29

Publications (2)

Publication Number Publication Date
RU2006142101A RU2006142101A (ru) 2008-06-20
RU2348409C2 true RU2348409C2 (ru) 2009-03-10

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006142101/14A RU2348409C2 (ru) 2004-04-29 2005-04-27 Способ снижения желудочно-кишечной токсичности, возникающей в результате применения тегафура

Country Status (16)

Country Link
US (1) US20080166427A1 (https=)
EP (1) EP1750703B1 (https=)
JP (1) JP5376758B2 (https=)
AT (1) ATE540679T1 (https=)
AU (1) AU2005237364B2 (https=)
CY (2) CY1112451T1 (https=)
DK (1) DK1750703T3 (https=)
ES (1) ES2378072T3 (https=)
HR (1) HRP20120293T1 (https=)
ME (1) ME01335B (https=)
PL (1) PL1750703T3 (https=)
PT (1) PT1750703E (https=)
RS (1) RS52217B (https=)
RU (1) RU2348409C2 (https=)
SI (1) SI1750703T1 (https=)
WO (1) WO2005105086A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
CN102648412A (zh) * 2009-07-17 2012-08-22 美瑞德生物工程公司 5-fu的检测方法
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) * 2014-03-28 2022-06-21 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
EP3290038A4 (en) * 2015-04-30 2018-12-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating adverse reaction to antitumor drug
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
US20250186435A1 (en) * 2020-05-19 2025-06-12 Cellix Bio Private Limited Pharmaceutical formulations and their preparations for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
NL194430C (nl) * 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
НАРИМАНОВ М.Н. Роль длительных инфузий 5-фторурацила в интермиттирующих режимах комбинированной химиотерапии опухолей желудочно-кишечного тракта. Автореф. дис. на соиск. учен. степ. канд. мед. наук. CHOLLET P. et al. Phase II trial with S-l in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTIC Early Clinical Studies Group (ECSG) // European Journal of Cancer, 2003, 39, p.1264-1270. YOSHISUE K. et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats // Drug Metab Dispos. 2000 Oct; 28(10), p.1162-1167. SHIRASAKA T. et al. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats // Cancer research, 1993, 53, Sep, p.4004-4009. *

Also Published As

Publication number Publication date
ATE540679T1 (de) 2012-01-15
DK1750703T3 (da) 2012-05-07
RS52217B (sr) 2012-10-31
ME01335B (me) 2013-12-20
SI1750703T1 (sl) 2012-02-29
AU2005237364A1 (en) 2005-11-10
EP1750703B1 (en) 2012-01-11
CY2012014I1 (el) 2016-04-13
AU2005237364B2 (en) 2010-07-08
US20080166427A1 (en) 2008-07-10
CY1112451T1 (el) 2015-12-09
EP1750703A1 (en) 2007-02-14
PL1750703T3 (pl) 2012-05-31
HRP20120293T1 (hr) 2012-04-30
WO2005105086A1 (en) 2005-11-10
JP2007534634A (ja) 2007-11-29
JP5376758B2 (ja) 2013-12-25
ES2378072T3 (es) 2012-04-04
PT1750703E (pt) 2012-02-23
CY2012014I2 (el) 2016-04-13
EP1750703A4 (en) 2008-02-27
RU2006142101A (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
RU2348409C2 (ru) Способ снижения желудочно-кишечной токсичности, возникающей в результате применения тегафура
Feun et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule
Temmink et al. Therapeutic potential of the dual‐targeted TAS‐102 formulation in the treatment of gastrointestinal malignancies
Álvarez et al. 5-Fluorouracil derivatives: a patent review
Maehara S-1 in gastric cancer: a comprehensive review
EP1849470B1 (en) Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
Chhetri et al. Current development of anti-cancer drug S-1
US20110190312A1 (en) Combinations Comprising Epothilones and Protein Tyrosine Kinase Inhibitors and Pharmaceutical Uses Thereof
AU2010247397B2 (en) Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
WO2010086964A1 (ja) がん治療のための併用療法
US20220323399A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
TW201912183A (zh) Hdac抑制劑與抗代謝藥劑組合用於癌症治療
Okamoto et al. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non–small-cell lung cancer
Roviello et al. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination
Scheulen et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
Yano et al. Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer—LOGIK 0601 study
Takechi et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts
US20100104565A1 (en) Combinations comprising dmxaa for the treatment of cancer
Mota et al. Review on TAS-102 development and its use for metastatic colorectal cancer
CN114650816A (zh) 用于治疗胆管癌的包含帕比司他的联合疗法
Fukushima et al. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents
AU2008356312A1 (en) Antitumor agent, kit, and method for treating cancer
Suzuki et al. Discovery and Development of Trifluridine/Tipiracil (Lonsurf™)
Morgan-Meadows et al. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
Backus et al. Chemotherapeutic strategies for treatment of colorectal cancer: present and future developments

Legal Events

Date Code Title Description
RZ4A Other changes in the information about an invention